A U.S. federal judge rejected Swiss drugmaker Novartis' request for a preliminary injunction to stop MSN Pharmaceuticals from ...

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug ...

Novartis could soon face generic competition for Entresto after judge's ruling.

NVS beats on Q2 earnings, raises 2025 income outlook on strong drug sales, but Cosentyx miss and CFO exit weigh on shares.

Divi's Labs makes active pharmaceutical ingredients for Entresto for Novartis, which contributes nearly 8% to Hyderabad-based ...

Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

A federal judge has denied Novartis (SIX:NOVN)’ request for a preliminary injunction that would have prevented MSN Pharmaceuticals from selling a generic version of heart medication Entresto.

CNBC's Karen Gilchrist weighs in on Novartis' second-quarter earnings and efforts to diversify its drug portfolio beyond its ...

In what is not exactly a win-win situation for the Indian generic firms, a recent federal court ruling in Delaware, USA, has ...

Novartis shares climb on strong Cosentyx sales, franchise growth, and a new malaria drug approval despite political risks.

The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” ...